A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L
D
-D, the protein based recognition-molecule being connected to the polymeric carrier by L
P
. Each occurrence of D is independently a therapeutic agent having a molecular weight≦5 kDa. L
D
and L
P
are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.
A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L
D
-D, the protein based recognition-molecule being connected to the polymeric carrier by L
P
. Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L
D
and L
P
are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.
Terminally Modified Polymers and Conjugates Thereof
申请人:Mersana Therapeutics, Inc.
公开号:US20140017265A1
公开(公告)日:2014-01-16
A terminally modified polymer is provided herein. At least one terminus of the polymer is —O—(CH
2
)
2
-L
M
or —O—CH
2
—CH(OH)—CH
2
—CR
1
═CR
2
R
3
. L
M
, R
1
, R
2
, and R
3
are defined herein Also disclosed are terminal conjugates comprising the polymer and a pharmaceutically useful modifier, as well as compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.
An auristatin compound conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L
D
-D, the protein based recognition-molecule being connected to the polymeric carrier by L
p
. Each occurrence of D is independently an auristatin compound having a molecular weight ≦5 kDa. L
D
and L
p
are distinct linkers connecting the auristatin compound and PBRM to the polymeric earner respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-auristatin compound-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.
A tubulysin compound conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L
D
-D, the protein based recognition-molecule being connected to the polymeric carrier by L
P
. Each occurrence of D is independently a tubulysin compound having a molecular weight≦5 kDa. L
D
and L
P
are distinct linkers connecting the tubulysin compound and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-tubulysin compound-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.